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Abstract
Background: Leprosy is an ancient infectious disease with a global annual incidence that has plateaued above 200,000
new cases since over a decade. New strategies are required to overcome this stalemate. Post-exposure prophylaxis (PEP)
with a single dose of Rifampicin (SDR) has conditionally been recommended by the World Health Organization (WHO),
based on a randomized-controlled-trial in Bangladesh. More evidence is required. The Post ExpOsure Prophylaxis for
Leprosy (PEOPLE) trial will assess effectiveness of different modalities of PEP on the Comoros and Madagascar.
Methods: PEOPLE is a cluster-randomized trial with villages selected on previous leprosy-incidence and randomly
allocated to four arms. Four annual door-to-door surveys will be performed in all arms. All consenting permanent
residents will be screened for leprosy. Leprosy patients will be treated according to international guidelines and eligible
contacts will be provided with SDR-PEP.
Arm-1 is the comparator in which no PEP will be provided. In arms 2, 3 and 4, SDR-PEP will be provided at double the
regular dose (20mg/kg) to eligible contacts aged two years and above. In arm 2 all household-members of incident
leprosy patients are eligible. In arm 3 not only household-members but also neighbourhood contacts living within 100-m
of an incident case are eligible. In arm 4 such neighbourhood contacts are only eligible if they test positive to anti-PGL-I, a
serological marker. Incidence rate ratios calculated between the comparator arm 1 and each of the intervention arms will
constitute the primary outcome.
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Discussion: Different trials on PEP have yielded varying results. The pivotal COLEP trial in Bangladesh showed a 57%
reduction in incidence over a two-year period post-intervention without any rebound in the following years. A study in a
high-incidence setting in Indonesia showed no effect of PEP provided to close contacts but a major effect of PEP
provided as a blanket measure to an entire island population. High background incidence could be the reason of the lack
of effect of PEP provided to individual contacts. The PEOPLE trial will assess effectiveness of PEP in a high incidence
setting and will compare three different approaches, to identify who benefits most from PEP.
Trial registration: Clinicaltrials.Gov. NCT03662022. Initial Protocol Version 1.2, 27-Aug-2018.
Keywords: Single dose rifampicin, Mapping, Clustering, Post exposure prophylaxis, Acceptability, Cost-effectiveness
Background
We describe the protocol of the PEOPLE study, a ran-
domized controlled trial on post exposure prophylaxis
(PEP) for leprosy on the Comoros and Madagascar. Lep-
rosy is an ancient infectious disease caused by Mycobac-
terium leprae. In humans, it is probably transmitted
through the air provoking skin and nerve lesions after
years without clinical manifestations. Delayed treatment
leads to complications including permanent deformity,
which in its turn leads to stigma.
Since 2000, leprosy has been declared eliminated as
public health problem worldwide, on the basis of a
prevalence rate of less than one per 10,000 population
[1]. Leprosy incidence however has plateaued above 200,
000 cases annually illustrating uninterrupted transmis-
sion. The study countries, Comoros and Madagascar,
both have high leprosy incidence and are included in the
list of 23 priority countries for leprosy control drawn up
by the World Health Organization (WHO) [2]. The
islands of Anjouan and Mohéli on the Comoros have
been reporting incidence rates close to 10 per 10,000
population for years. In some villages on Anjouan door-
to-door screening in 2017 revealed prevalence rates of
up to 2% [3]. Madagascar notified 1424 new leprosy
cases in 2018 on a population of approximately 26 mil-
lion, 9% were children. (2) However, the epidemiological
burden varies between the districts, explained by differ-
ent access related issues such as geographical, availability
of qualified health staff, health-seeking awareness, etc.
For this study, a hyperendemic district, Miandrivazo, has
been selected.
Providing a single dose of Rifampicin (SDR) as PEP to
contacts of leprosy patients has been conditionally en-
dorsed by WHO as a strategy to overcome the current
stalemate [4, 5]. This recommendation is mainly based on
the ‘contact transmission and chemoprophylaxis in lep-
rosy’ (COLEP) trial in Bangladesh that demonstrated a
57% reduction of leprosy incidence over a two-year period
following provision of SDR to household and social con-
tacts of leprosy patients [6]. However in high endemicity
settings in Indonesia, two monthly doses of Rifampicin
administered to household and social contacts of leprosy
patients had no effect, in contrast with providing PEP to
an entire island population that resulted in a threefold
reduction of leprosy incidence [7].
Methods/design
Objectives and hypothesis
In this study we intend to compare effectiveness as well as
cost effectiveness of three different modalities of SDR-PEP
to a comparator arm in which no PEP is provided.
Study design
The study has been designed as a cluster randomized
trial in which villages will be randomly allocated to four
arms. All villages will be subject to four annual rounds
of door-to-door screening. Leprosy patients identified
will be treated in accordance with international guide-
lines, contacts will be provided PEP in accordance with
the study arm. In arm 1, the comparator arm, no PEP
will be provided. In arm 2 all asymptomatic household
members will receive SDR-PEP. In arm 3 SDR-PEP will
be provided to all leprosy asymptomatic household-
embers plus neighbourhood contacts residing within a
100-m radius from an index case household. Finally, in
arm 4 SDR-PEP will be provided to all household mem-
bers and to those residing within 100-m of an index case
and testing positive to anti-phenolic glycolipid-I (anti-
PGL-I), a test for detection of IgM antibodies to
M. leprae. If the village population in a 100-m radius
around households of index cases comprises ≥50% in arm
3 or ≥ 75% in arm 4, the entire village will in principle
be eligible for SDR-PEP.
Setting
The Union des Comores is an island nation in the
Indian Ocean, north of Madagascar. On the main island,
Grande Comore, leprosy has become a rare disease but
the islands of Anjouan and Mohéli are still notifying
around 400 new leprosy cases annually on an estimated
population of 450,000.
The Comoros has for decades had a strong leprosy
control program, achieving good coverage and fully in
line with the strategies recommended by WHO. Even
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though early case finding is achieved, with less than 3% of
visible deformities in new leprosy patients, transmission
has remained high. This is reflected in a 27% proportion
of children under 15 years of age among new patients.
Madagascar has a population of 26 million and notifies
around 1500 leprosy cases annually. However, leprosy
control program coverage is patchy and case detection is
often late, reflected in a proportion of new patients pre-
senting with visible deformities close to 20%. The pro-
portion of children among incident leprosy patients is
lower than on the Comoros but remains significant at
9% [2]. The district of Miandrivazo selected for this
study is located in the Menabe area on the central west
of Madagascar. More specifically, the study takes place
in the southern part of the district which is mainly rural
and relatively sparsely populated with numerous small
and remote villages. Coverage of leprosy control services
in that area has been limited and reliable incidence data
have not yet been available for recent years. The first
round of screening in Madagascar will therefore be used
as a baseline survey, randomization will only be done
upon its completion.
Participants
Participants will be recruited from 48 villages on the
Comoros (32 on Anjouan and 16 on Mohéli) and a
number of villages yet to be determined in Miandrivazo
district of Madagascar. Leprosy screening will be offered
to both genders and all ages, if required treatment will
be provided. PEP however will only be provided to those
permanent residents aged two years or above who did
not receive Rifampicin in the past two years. Another
exclusion criterion is having cough of more than two
weeks’ duration (presumptive pulmonary tuberculosis).
Randomization
On Anjouan and Mohéli (Comoros) the randomization
has been done at village level based on reported leprosy in-
cidence in the years 2013–2017. Villages had been grouped
by island in decreasing order of incidence in blocks of four.
Within each block villages were randomly allocated to one
of the four study arms in a mutually exclusive manner,
using random numbers generated in Excel.
For Miandrivazo district (Madagascar) the randomization
will be done at the end of the first year of 2019 after com-
pletion of the door-to-door active case detection carried
out during the first year of the study. A number of high
prevalence villages with a total population of ideally close
to 20,000 will be selected, taking care of having a fourfold
(e.g. 16 or 20). These will then be grouped into blocks of
four based on prevalence and randomized over the four
study arms within each block similarly to the procedure
used on the Comoros.
Outcome measures
The principal outcome measure will be the leprosy inci-
dence rates in each of the four study arms. The incidence
rates in the Comoros will be measured between the first
and the fourth door-to-door survey, while the incidence
rates in Madagascar will be evaluated between the second
and fourth survey round. The incidence rate ratios will then
be calculated between the comparator arm (arm 1) and
each of the intervention arms. In addition, the costs of
screening and PEP provision in each of the four arms will
be determined allowing to calculate a cost per leprosy case
averted for each of the intervention arms with the compara-
tor arm as baseline. Spatial clustering of leprosy at sub-
village level will be assessed by comparing incidence rates
within households of index cases and incidence among
neighbourhood contacts at varying distances (< 25m, 25–
50m, 50–75m and 75–100m) to incidence rates among
those living at more than 100m from any index case.
Intervention implementation and data collection
Door-to-door screening will be conducted, covering all
study villages once yearly for a total of four consecutive
years. In addition to leprosy the study will focus on skin
diseases. Treatment will be provided for common minor
skin conditions such as fungal infections or scabies. Lep-
rosy patients detected will be treated according to the
guidelines from the national leprosy control program.
In each household screened, name, age and gender of
each permanent household member will be recorded on
a paper form during the visit. This form, of which one
copy will be used per household, has a unique serial
number. It has one line per person, each line with a
space to sign for informed consent and a pre-printed
unique barcode. These forms will be used to enter form
serial number and name, age, gender and barcode of
each individual in a database in MS Access. All other
data will be recorded through an Android application
made in Open Data Kit Collect (ODK). The serial num-
ber will be copied from the paper form into the app for
each household, for each individual the corresponding
barcode will be scanned. Apart from form serial number
and barcodes, the app will also be used to record the
date of visit, Global Positioning System (GPS) coordi-
nates of the household, village name, and number of
household members. For each household member we
will record whether the person was present, whether the
person has a history of leprosy, whether (s)he was exam-
ined and what was the result of the clinical exam. We
will also record the presence or absence of a Bacille de
Calmette Guérin (BCG) scar and ask for cough of more
than two week’s duration. These data are uploaded to a
secure server whenever a village is completed. Names
will not be recorded in the Android application but can
be retrieved from the Access database if required based
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on the barcodes (e.g. for treatment of leprosy). Thus,
exact records will be available on numbers of persons
living in the households visited, numbers screened, num-
bers of cases identified and the date and location of
screening activities.
Participants with cough for more than two weeks iden-
tified during surveys will have a sputum sample collected
for tuberculosis screening. Those with confirmed tuber-
culosis will be treated according to the national tubercu-
losis guidelines.
Leprosy diagnosis will be clinical, based on the presence
of three cardinal signs: patch with loss of sensation, en-
larged peripheral nerves and/or slit-skin smear (SSS) posi-
tive for acid fast bacilli. All leprosy cases diagnosed will be
verified by experienced leprosy national control program
staff. If confirmed they will be treated according to WHO
guidelines. Conditional upon their informed consent, inci-
dent leprosy patients will be enrolled in a sub study in
which slit skin smears, nasal swabs and skin biopsies will
be sampled. Biopsies will be subjected to quantitative
polymerase chain reaction (qPCR) for Mycobacterium
leprae. In the framework of a sub-study, not part of this
protocol, genotyping of bacillary DNA will be performed
on all qPCR positive samples.
SDR-PEP will be provided to all household members
in arms 2, 3 and 4 as soon as a new leprosy case is
detected. Children below two years of age and persons
having received Rifampicin within the last 24 months
will be excluded. In Comoros, a new leprosy case is de-
fined in the first round as a case arising after the 31st of
December, 2017 (or after the 31st of December, 2018 in
Madagascar), and in subsequent rounds as a case arising
after the previous screening round.
In arms 3 and 4 PEP will also be provided to neigh-
bourhood contacts living within 100 m of an index case.
This will only be done once the entire village has been
screened. Selection of the group of individuals living
within 100 m of an incident case will be done after ana-
lysing cleaned data by the principal investigators in each
island and the research coordinator at the Institute of
Tropical Medicine, Antwerp. As explained earlier, in
arm 4 non-household contacts living within 100m of an
index case are eligible for PEP only if they are positive to
anti-PGL-I. In arm 3, if 50% or more of the population
live within 100 m of an index case, the entire village will
be considered eligible. This will be the case in arm 4 if
75% or more live within 100 m of an index case.
Detailed costs of screening and PEP implementation will
be recorded for each study arm including direct costs for
direct implementation, monitoring and support.
Post exposure prophylaxis
As post exposure prophylaxis we will use a single dose
of Rifampicin, in accordance with the WHO guidelines.
However, the dose used will be higher than the standard
dose. Rifampicin has for decades been a core drug for the
treatment of tuberculosis (TB). The dosage of 10mg/kg
recommended in the 1970s was established balancing con-
cerns on toxicity and cost [8] However, this dose might
not be optimal in terms of efficacy. A study using Rifampi-
cin at 20mg/kg daily in treatment of TB demonstrated a
doubling in early bactericidal activity compared to the
standard dose [9] In another TB study, two weeks of Ri-
fampicin at a dose of 35mg/kg was well tolerated without
increase in toxicity [8] The recent study ‘Optimization of
the TB Treatment Regimen Cascade (OneRIF, Clinical-
Trials.gov Identifier: NCT02153528)’ documented no in-
creased toxicity in 475 adults treated with Rifampicin at
20mg/kg for six months as part of the treatment of drug-
susceptible TB, compared to 468 adults that were treated
with Rifampicin at 10mg/kg.
There are also precedents of using Rifampicin at high
doses for leprosy post-exposure prophylaxis and treat-
ment. In the French Polynesia Rifampicin at 25 mg/kg
was used as post-exposure prophylaxis [10–12]. Single
dose of Rifampicin at 40 mg/kg was effective and safe for
the treatment of PB cases with a negative bacillary index
[13]. In the PEOPLE trial we therefore opted for Rifam-
picin in a single a dosage of 20 mg/kg, which we will
refer to as ‘Single Double Dose Rifampicin Post Exposure
Prophylaxis’ or ‘SDDR-PEP’.
SDDR-PEP will be provided under supervision of a
village health worker who will keep a record of each per-
son eligible and whether or not this person has taken his
dose. As higher Rifampicin dosage has been documented
safe [8, 10–12], we will implement passive adverse events
(AE) surveillance. An AE is defined as any unexpected
event in a clinical investigation after administering a
pharmaceutical product, it does not necessarily imply a
causal relationship. A distinction will be made between AE’s
and serious AE’s (SAE), the latter defined as an AE that pro-
vokes death or is life-threatening, requiring hospitalization
or increase in duration of existing hospitalization, or results
in permanent disability /incapacity or provokes a con-
genital anomaly/ birth defect. We will record all AE
and SAE occurring within 72 h of Rifampicin adminis-
tration and classify them according to severity and
probable relationship to SDDR-PEP. Also, health
workers in charge of the selected villages will be in-
formed about the PEOPLE trial and advised to report
any AE or SAE. In case of SAE a specific template will
be recorded and sent to pharmacovigilance unit of
ITM within 24 h.
It has been documented that the risk of inducing
Rifampicin resistance in undiagnosed TB or leprosy as a
result of a single dose of Rifampicin is negligible [14].
Rifampicin resistance in TB can occur under monother-
apy but that requires longer exposure [15]. In order to
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minimize the risk of Rifampicin resistance we will screen
for TB and exclude all presumptive TB with cough of
more than two weeks. Also, every person that has received
Rifampicin within less than two years will be excluded
from SDR-PEP. Finally, we will monitor Rifampicin resist-
ance in leprosy through molecular testing on qPCR posi-
tive samples from leprosy cases.
Rifampicin interacts with drugs such as anti-retrovirals
(ARV) [16] that are known as inducer of a number of
genes controlling drug metabolism and transport like
cytochrome P450 isoenzymes and the drug efflux pump
p-glycoprotein. Therefore, concentration of Rifampicin
administered with ARV may decrease. As we are provi-
ding a single dose and given that the Rifampicin serum
half-life is less than five hours such interaction effect can
be considered negligible irrespective of the dosing [17].
Rationale
Effectiveness of PEP probably depends on the leprosy
epidemiological burden, the type of contacts targeted
and the type of PEP-regimen. Targeting household con-
tacts only avoids issues of confidentiality but may lack
effectiveness. Also targeting social contacts, as was done
in the COLEP trial in Bangladesh, is probably more ef-
fective [6]. However, this approach may even not be ef-
fective in hyper endemic settings as suggested in a study
performed in Indonesia [18].
Another important factor to consider is the regimen
used. In the COLEP trial a 50–60% reduction in inci-
dence was achieved after administering a single dose of
Rifampicin at 10 mg/kg [6]. An expert committee con-
vened in preparation of the PEP++ trial, which is to start
soon, drafted a reinforced PEP regimen based on three
monthly doses of Rifampicin plus Clarithromycin [19].
In the PEOPLE trial we choose to adopt a regimen that
includes only one single dose of PEP for logistical and
cost reasons.
Data analysis
For our main analysis we will fit a random effects
Poisson model (or negative binomial if overdispersed)
comparing incidence rates between the first and fourth
survey round in arms 2, 3 and 4 with those of the com-
parator arm 1 (starting from the second survey round in
Madagascar). As random effects we will use island
(Anjouan, Mohéli or Madagascar), ‘block’, i.e. the groups
of four villages arranged in order of incidence initially
used in the randomization process and village. We will
thus obtain incidence rate ratios between arm 1 and
each of the other arms. Considering the fact that three
comparisons will be performed, a p-value of 0.017 will
be used as threshold of statistical significance.
Spatial clustering will be assessed by calculating for
each individual the distance to the nearest leprosy
affected household in the previous year [20]. Household
coordinates will be plotted in Quantum GIS version 3.8
Zanzibar. We will then calculate the distance to the
nearest index case household for each household using
the distance matrix tool. As a next step subjects will be
divided into six categories: household contacts, neigh-
bours at less than 25m and neighbourhood contacts be-
tween 25 and 50m, 50–75m and 75–100 m and at more
than 100 m. Incidence rate ratios for leprosy will be cal-
culated with individuals living at more than 100m as
reference category and village as random effect.
Results of spatial analysis will be triangulated with re-
sults of phylogenetic of M. leprae clustering observed in
the sub study in which skin biopsy samples are collected
from each consenting incident leprosy patient.
Both average cost per person screened for leprosy per
island and the average cost per leprosy patient detected
per study arm will be assessed. Cost data will be gath-
ered throughout the study. All incremental costs will be
calculated by using comparator arm as a baseline.
Sample size
The calculation of sample size is based on the primary
objective and according to the methodology described
by Hayes and Bennet for pair matched randomized con-
trolled trials [21]. The incidence rate in the comparator
arm with no PEP will be compared to each of the three
intervention arms. We assumed that the annual inci-
dence rate in the comparator arm will be 1.5/1000, based
on data from 48 villages on the Comoros for the years
2013 to 2017. We expected a reduction of the leprosy in-
cidence of 50% in any of the intervention arms. As three
comparisons will be made, we opted for a significance
level of 0.017.
Based on data from the Comoros we calculated a coeffi-
cient of variation k between clusters of 0.29. With an aver-
age cluster size of 2400, to achieve a power of 80%, we will
need 13 clusters per study arm, i.e. 4* 31,200 participants.
In order to compensate for inaccuracies in census data, as
well as for absentees and non-responders, we decided to
aim for 36,000 participants per study arm, i.e. 15% extra.
Therefore, the total sample size is expected to be 124,000
and 20,000 to be recruited in the Comoros and in
Madagascar respectively.
Ethics
The study will be carried out according to the principles
stated in the Declaration of Helsinki, all applicable regu-
lations and according to established international scien-
tific standards. The choice of treatment for the leprosy
patients will not depend on the results of the PEOPLE
study, but on the current national leprosy guidelines.
The study has been approved by the ‘Comité d’Éthique
de la Recherche Biomédicale’ (CERBM) in Madagascar
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and the ‘Comité National d’Éthique pour les Sciences de
la Vie et de la Santé’ (CNESS) in the Comoros. Approval
has also been obtained from the Institutional Review
Board (IRB) of ITM given that ITM is the sponsor of
this study. In addition, the study has been approved by
the Ethics Committee (EC) of the University of Antwerp
Hospital in Antwerp.
Prior to the start, this study has been included in the Clin-
icaltrials.gov public registry (NCT03662022, on 7 September
2018, https://clinicaltrials.gov/ct2/show/NCT03662022).
Discussion
Although single dose Rifampicin post exposure prophylaxis
has now been conditionally endorsed by WHO [5], a lot of
debate remains. Some argue that SDR will mainly prevent
paucibacillary leprosy which is less infectious or that SDR
may just postpone new cases rather than preventing them.
Others argue that SDR might eventually lead to resistance
of M. leprae against Rifampicin [22]. The pivotal COLEP
trial in Bangladesh did not provide any such indications.
There was a clear incidence reduction of 50–60%, without
any rebound after the intervention ended [6]. However, evi-
dence from more than one site is required and other op-
tions of PEP need to be explored. As was explained earlier
we do opt for a higher dose of Rifampicin, hoping the in-
creased early bactericidal effect observed for M. tuberculosis
will also apply to M. leprae.
The PEOPLE trial is the second major randomized con-
trolled trial on post-exposure prophylaxis for leprosy after
the COLEP trial. It is implemented against a background
of very high leprosy incidence, which may have a major
implication for effectiveness of PEP. The PEOPLE trial
therefore includes two different approaches to PEP, target-
ing only household members and targeting entire commu-
nities. In addition, we will assess the feasibility and
effectiveness of selecting neighbourhood contacts eligible
for PEP based on presence of antibodies against M. leprae.
Use of innovative digital tools for data collection and
mapping allows geospatial patterns in leprosy transmis-
sion to be assessed, which can at a later stage be triangu-
lated with results of phylogenetic clustering genotypes of
M. leprae found in the patients. PCR results from the
sub study will also allow the accuracy of diagnostic pro-
cedures to be validated.
Costing and cost effectiveness are also part of the study.
Thus, once completed we will be able to provide answers
relevant for leprosy control programs concerned with
questions on feasibility and cost of PEP implementation.
As a by-product of this study we are establishing a very
well characterized cohort of leprosy patients for which clin-
ical information, samples and precise geographical location
will be available. This cohort would allow other pertinent
research questions to be answered such as risks for relapse
and drug resistance [23].
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